Skip to main content

Table 1 Clinical parameters of patients with PsA at baseline and 12 weeks following treatment

From: Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study

  Anakinra n = 10    Etanercept n = 15   
  Week 0 Week 12 P-value Week 0 Week 12 P-value
TJC28 9.5 (3 to 19) 7 (1 to 13) 0.033 11 (1 to 25) 2 (0 to 28) 0.004
TJC68 24.5 (9 to 52) 13.5 (3 to 35) 0.015 15 (3 to 57) 3 (0 to 38) 0.002
SJC28 8 (1 to 18) 5 (0 to 8) 0.032 4 (1 to 21) 1 (0 to 8) 0.005
SJC68 20.5 (6 to 27) 8 (0 to 23) 0.028 9 (3 to 43) 2 (0 to 16) 0.007
ESR 18.5 (3 to 79) 7.5 (2 to 46) 0.059 14 (4 to 91) 5 (1 to 26) 0.001
CRP 17 (4 to 70) 7.5 (0 to 29) 0.044 7 (0 to 42) 0 (0 to 18) 0.092
d VAS 66 (27 to 85) 47 (12 to 70) 0.051 44.5 (5 to 93) 15 (2 to 56) 0.002
p VAS 65.5 (21 to 91) 46.5 (20 to 75) 0.169 50 (22 to 93) 12 (2 to 66) 0.001
HAQ 1.25 (0.75 to 2.38) 1.13 (0.25 to 1.88) 0.057 1.13 (0 to 2.5) 0.25 (0 to 2.25) 0.01
DAS28 5.03 (3.77 to 7.16) 4.17 (2.35 to 5.98) 0.022 5.26 (3.08 to 6.95) 2.01 (0.14 to 5.35) 0.001
  1. Median (range). d VAS, disease visual analogue scale; p VAS, pain visual analogue scale.